SEC Info - Oncocyte Corp. - ‘10-K’ for 12/31/21

SEC Info℠

Home

My Interests

Help

Please Sign In

Oncocyte Corp. – ‘10-K’ for 12/31/21 – ‘EX-101.DEF’

On: Friday, 3/11/22, at 5:17pm ET · For: 12/31/21 · Accession #: 1493152-22-6677 · File #: 1-37648

Previous ‘10-K’: ‘10-K/A’ on 4/30/21 for 12/31/20 · Next: ‘10-K/A’ on 5/2/22 for 12/31/21 · Latest: ‘10-K’ on 4/16/24 for 12/31/23 · 42 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/11/22  Oncocyte Corp.                    10-K       12/31/21   90:10M                                    M2 Compliance LLC/FA

Annual Report — Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.76M 
 2: EX-4.11     Instrument Defining the Rights of Security Holders  HTML     27K 
 3: EX-10.43    Material Contract                                   HTML    236K 
 4: EX-21       Subsidiaries List                                   HTML     26K 
 5: EX-23.1     Consent of Independent Registered Public            HTML     25K 
                Accounting Firm                                                  
 6: EX-23.2     Consent of Independent Registered Public            HTML     25K 
                Accounting Firm                                                  
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     32K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     31K 
 9: EX-32.1     Certification -- §906 - SOA'02                      HTML     27K 
15: R1          Cover                                               HTML     97K 
16: R2          Consolidated Balance Sheets                         HTML    139K 
17: R3          Consolidated Balance Sheets (Parenthetical)         HTML     43K 
18: R4          Consolidated Statements of Operations               HTML    104K 
19: R5          Consolidated Statements of Comprehensive Loss       HTML     43K 
20: R6          Consolidated Statements of Shareholders' Equity     HTML     97K 
21: R7          Consolidated Statements of Cash Flows               HTML    156K 
22: R8          Organization, Description of the Business and       HTML     53K 
                Liquidity                                                        
23: R9          Basis of Presentation and Summary of Significant    HTML    153K 
                Accounting Policies                                              
24: R10         Business Combinations                               HTML    224K 
25: R11         Goodwill and Intangible Assets, net                 HTML     54K 
26: R12         Shareholders? Equity                                HTML     49K 
27: R13         Stock-Based Compensation                            HTML    134K 
28: R14         Disaggregation of Revenues and Concentration Risk   HTML     67K 
29: R15         Income Taxes                                        HTML     77K 
30: R16         Right-of-use Assets, Machinery and Equipment, Net   HTML     37K 
                and Construction in Progress                                     
31: R17         Commitments and Contingencies                       HTML     89K 
32: R18         Related Party Transactions                          HTML     45K 
33: R19         Loan Payable to Silicon Valley Bank                 HTML     47K 
34: R20         Quarterly Financial Data (Unaudited)                HTML     67K 
35: R21         Subsequent Events                                   HTML     42K 
36: R22         Basis of Presentation and Summary of Significant    HTML    225K 
                Accounting Policies (Policies)                                   
37: R23         Basis of Presentation and Summary of Significant    HTML     48K 
                Accounting Policies (Tables)                                     
38: R24         Business Combinations (Tables)                      HTML    131K 
39: R25         Goodwill and Intangible Assets, net (Tables)        HTML     54K 
40: R26         Stock-Based Compensation (Tables)                   HTML    115K 
41: R27         Disaggregation of Revenues and Concentration Risk   HTML     72K 
                (Tables)                                                         
42: R28         Income Taxes (Tables)                               HTML     58K 
43: R29         Right-of-use Assets, Machinery and Equipment, Net   HTML     35K 
                and Construction in Progress (Tables)                            
44: R30         Commitments and Contingencies (Tables)              HTML     62K 
45: R31         Quarterly Financial Data (Unaudited) (Tables)       HTML     65K 
46: R32         Organization, Description of the Business and       HTML     82K 
                Liquidity (Details Narrative)                                    
47: R33         Schedule of Prepaid Expenses and Other Current      HTML     38K 
                Assets (Details)                                                 
48: R34         Schedule of Reconciliation of Cash, Cash            HTML     34K 
                Equivalents, and Restricted Cash (Details)                       
49: R35         Schedule of Common Stock Equivalents Excluded from  HTML     33K 
                Computation of Diluted Net Loss Per Share of                     
                Common Stock (Details)                                           
50: R36         Basis of Presentation and Summary of Significant    HTML     75K 
                Accounting Policies (Details Narrative)                          
51: R37         Schedule of Fair Value of Aggregate Merger          HTML     49K 
                Consideration (Details)                                          
52: R38         Schedule of Fair Value of Aggregate Merger          HTML     33K 
                Consideration (Details) (Parenthetical)                          
53: R39         Schedule of Intangible Assets Acquired and          HTML     65K 
                Liabilities Assumed (Details)                                    
54: R40         Schedule of Identifiable Intangible Assets and      HTML     34K 
                Estimated Useful Life (Details)                                  
55: R41         Schedule of Fair Value of Contingent Consideration  HTML     42K 
                Liability (Details)                                              
56: R42         Schedule of Contingent Consideration, Measured at   HTML     43K 
                Fair Value (Details)                                             
57: R43         Schedule of Acquisition Intangible Assets           HTML     44K 
                (Details)                                                        
58: R44         Summary of Acquisition Intangible Assets (Details)  HTML     29K 
                (Parenthetical)                                                  
59: R45         Schedule of Condensed Statement of Operations       HTML     49K 
                (Details)                                                        
60: R46         Business Combinations (Details Narrative)           HTML    223K 
61: R47         Schedule of Goodwill and Intangible Assets          HTML     58K 
                (Details)                                                        
62: R48         Schedule of Intangible Assets Future Amortization   HTML     41K 
                Expense (Details)                                                
63: R49         Shareholders? Equity (Details Narrative)            HTML     79K 
64: R50         Summary of Stock Option Activity (Details)          HTML    101K 
65: R51         Schedule of Stock Options Outstanding, Vested and   HTML     50K 
                Exercisable (Details)                                            
66: R52         Summary of Stock-based Compensation Expense         HTML     39K 
                (Details)                                                        
67: R53         Schedule of Assumptions Used to Calculate Fair      HTML     35K 
                Value of Stock Options (Details)                                 
68: R54         Stock-Based Compensation (Details Narrative)        HTML     76K 
69: R55         Schedule of Consolidated Revenues Attributable to   HTML     39K 
                Products or Services (Details)                                   
70: R56         Schedule of Consolidated Revenues Generated by      HTML     46K 
                Unaffiliated Customers (Details)                                 
71: R57         Schedule of Percentage of Consolidated Revenues     HTML     38K 
                Attributable to Geographical Locations (Details)                 
72: R58         Schedule of Percentage of Total Consolidated        HTML     37K 
                Accounts Receivables (Details)                                   
73: R59         Schedule of Components of Deferred Tax Assets and   HTML     56K 
                Liabilities (Details)                                            
74: R60         Schedule of Income Tax Reconciliation (Details)     HTML     45K 
75: R61         Schedule of Unrecognized Tax Benefit (Details)      HTML     35K 
76: R62         Income Taxes (Details Narrative)                    HTML     80K 
77: R63         Schedule of Right-of-use Assets, Machinery and      HTML     41K 
                Equipment, Net, and Construction in Progress                     
                (Details)                                                        
78: R64         Right-of-use Assets, Machinery and Equipment, Net   HTML     28K 
                and Construction in Progress (Details Narrative)                 
79: R65         Schedule of Supplemental Cash Flow Information      HTML     35K 
                Related to Operating and Financing Lease (Details)               
80: R66         Schedule of Supplemental Balance Sheet Information  HTML     60K 
                Related to Operating and Financing Leases                        
                (Details)                                                        
81: R67         Schedule of Future Minimum Lease Commitments for    HTML     65K 
                Operating and Financing Leases (Details)                         
82: R68         Commitments and Contingencies (Details Narrative)   HTML     66K 
83: R69         Related Party Transactions (Details Narrative)      HTML     70K 
84: R70         Loan Payable to Silicon Valley Bank (Details        HTML     72K 
                Narrative)                                                       
85: R71         Schedule of Quarterly Financial Information         HTML     79K 
                (Details)                                                        
88: XML         IDEA XML File -- Filing Summary                      XML    161K 
86: XML         XBRL Instance -- form10-k_htm                        XML   2.12M 
87: EXCEL       IDEA Workbook of Financial Reports                  XLSX    145K 
11: EX-101.CAL  Inline XBRL Taxonomy Extension Calculation           XML    220K 
                Linkbase Document -- ocx-20211231_cal                            
12: EX-101.DEF  Inline XBRL Taxonomy Extension Definition Linkbase   XML    850K 
                Document -- ocx-20211231_def                                     
13: EX-101.LAB  Inline XBRL Taxonomy Extension Label Linkbase        XML   1.55M 
                Document -- ocx-20211231_lab                                     
14: EX-101.PRE  Inline XBRL Taxonomy Extension Presentation          XML   1.19M 
                Linkbase Document -- ocx-20211231_pre                            
10: EX-101.SCH  Inline XBRL Taxonomy Extension Schema Document --    XSD    238K 
                ocx-20211231                                                     
89: JSON        XBRL Instance as JSON Data -- MetaLinks              461±   647K 
90: ZIP         XBRL Zipped Folder -- 0001493152-22-006677-xbrl      Zip    520K

‘EX-101.DEF’ — Inline XBRL Taxonomy Extension Definition Linkbase Document — ocx-20211231_def

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://oncocyte.com/role/Cover" xlink:href="ocx-20211231.xsd#Cover" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/BalanceSheets" xlink:href="ocx-20211231.xsd#BalanceSheets" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/BalanceSheetsParenthetical" xlink:href="ocx-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/StatementsOfOperations" xlink:href="ocx-20211231.xsd#StatementsOfOperations" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:href="ocx-20211231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/StatementsOfShareholdersEquity" xlink:href="ocx-20211231.xsd#StatementsOfShareholdersEquity" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/StatementsOfCashFlows" xlink:href="ocx-20211231.xsd#StatementsOfCashFlows" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:href="ocx-20211231.xsd#OrganizationDescriptionOfBusinessAndLiquidity" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="ocx-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinations" xlink:href="ocx-20211231.xsd#BusinessCombinations" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/GoodwillAndIntangibleAssetsNet" xlink:href="ocx-20211231.xsd#GoodwillAndIntangibleAssetsNet" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquity" xlink:href="ocx-20211231.xsd#ShareholdersEquity" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensation" xlink:href="ocx-20211231.xsd#Stock-basedCompensation" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk" xlink:href="ocx-20211231.xsd#DisaggregationOfRevenuesAndConcentrationRisk" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxes" xlink:href="ocx-20211231.xsd#IncomeTaxes" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:href="ocx-20211231.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingencies" xlink:href="ocx-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactions" xlink:href="ocx-20211231.xsd#RelatedPartyTransactions" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" xlink:href="ocx-20211231.xsd#LoanPayableToSiliconValleyBank" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/QuarterlyFinancialData" xlink:href="ocx-20211231.xsd#QuarterlyFinancialData" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/SubsequentEvents" xlink:href="ocx-20211231.xsd#SubsequentEvents" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ocx-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ocx-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinationsTables" xlink:href="ocx-20211231.xsd#BusinessCombinationsTables" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/GoodwillAndIntangibleAssetsNetTables" xlink:href="ocx-20211231.xsd#GoodwillAndIntangibleAssetsNetTables" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensationTables" xlink:href="ocx-20211231.xsd#Stock-basedCompensationTables" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:href="ocx-20211231.xsd#DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxesTables" xlink:href="ocx-20211231.xsd#IncomeTaxesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:href="ocx-20211231.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesTables" xlink:href="ocx-20211231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/QuarterlyFinancialDataTables" xlink:href="ocx-20211231.xsd#QuarterlyFinancialDataTables" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:href="ocx-20211231.xsd#OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ocx-20211231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="ocx-20211231.xsd#ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:href="ocx-20211231.xsd#ScheduleOfCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ocx-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFairValueOfAggregateMergerConsiderationDetails" xlink:href="ocx-20211231.xsd#ScheduleOfFairValueOfAggregateMergerConsiderationDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFairValueOfAggregateMergerConsiderationDetailsParenthetical" xlink:href="ocx-20211231.xsd#ScheduleOfFairValueOfAggregateMergerConsiderationDetailsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfIntangibleAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="ocx-20211231.xsd#ScheduleOfIntangibleAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfIdentifiableIntangibleAssetsAndEstimatedUsefulLifeDetails" xlink:href="ocx-20211231.xsd#ScheduleOfIdentifiableIntangibleAssetsAndEstimatedUsefulLifeDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:href="ocx-20211231.xsd#ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:href="ocx-20211231.xsd#ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfAcquisitionIntangibleAssetsDetails" xlink:href="ocx-20211231.xsd#ScheduleOfAcquisitionIntangibleAssetsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/SummaryOfAcquisitionIntangibleAssetsDetailsParenthetical" xlink:href="ocx-20211231.xsd#SummaryOfAcquisitionIntangibleAssetsDetailsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfCondensedStatementOfOperationsDetails" xlink:href="ocx-20211231.xsd#ScheduleOfCondensedStatementOfOperationsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" xlink:href="ocx-20211231.xsd#BusinessCombinationsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:href="ocx-20211231.xsd#ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:href="ocx-20211231.xsd#ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" xlink:href="ocx-20211231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" xlink:href="ocx-20211231.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfStockOptionsOutstandingVestedAndExercisableDetails" xlink:href="ocx-20211231.xsd#ScheduleOfStockOptionsOutstandingVestedAndExercisableDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" xlink:href="ocx-20211231.xsd#SummaryOfStock-basedCompensationExpenseDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:href="ocx-20211231.xsd#ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="ocx-20211231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:href="ocx-20211231.xsd#ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:href="ocx-20211231.xsd#ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:href="ocx-20211231.xsd#ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfPercentageOfTotalConsolidatedAccountsReceivablesDetails" xlink:href="ocx-20211231.xsd#ScheduleOfPercentageOfTotalConsolidatedAccountsReceivablesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="ocx-20211231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfIncomeTaxReconciliationDetails" xlink:href="ocx-20211231.xsd#ScheduleOfIncomeTaxReconciliationDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfUnrecognizedTaxBenefitDetails" xlink:href="ocx-20211231.xsd#ScheduleOfUnrecognizedTaxBenefitDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxesDetailsNarrative" xlink:href="ocx-20211231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:href="ocx-20211231.xsd#ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:href="ocx-20211231.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:href="ocx-20211231.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:href="ocx-20211231.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:href="ocx-20211231.xsd#ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ocx-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ocx-20211231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" xlink:href="ocx-20211231.xsd#LoanPayableToSiliconValleyBankDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfQuarterlyFinancialInformationDetails" xlink:href="ocx-20211231.xsd#ScheduleOfQuarterlyFinancialInformationDetails" xlink:type="simple"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Cover" xlink:title="00000001 - Document - Cover"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Shareholders' Equity">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_10" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_50"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockIssuedDuringPeriodValueOfSaleOfCommonSharesUnderAtthemarketTransactions" xlink:label="loc_OCXStockIssuedDuringPeriodValueOfSaleOfCommonSharesUnderAtthemarketTransactions_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodValueOfSaleOfCommonSharesUnderAtthemarketTransactions_50" xlink:type="arc" order="8"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockIssuedDuringPeriodSharesSaleOfCommonSharesUnderAtthemarketTransactionsShares" xlink:label="loc_OCXStockIssuedDuringPeriodSharesSaleOfCommonSharesUnderAtthemarketTransactionsShares_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodSharesSaleOfCommonSharesUnderAtthemarketTransactionsShares_50" xlink:type="arc" order="9"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockIssuedDuringPeriodValueFinancingCostsForAtthemarketTransactions" xlink:label="loc_OCXStockIssuedDuringPeriodValueFinancingCostsForAtthemarketTransactions_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodValueFinancingCostsForAtthemarketTransactions_50" xlink:type="arc" order="10"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_OCXStockIssuedDuringPeriodValueWarrantsExercised_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodValueWarrantsExercised_50" xlink:type="arc" order="13"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_OCXStockIssuedDuringPeriodSharesWarrantsExercised_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodSharesWarrantsExercised_50" xlink:type="arc" order="14"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes" xlink:label="loc_OCXSharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXSharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes_50" xlink:type="arc" order="15"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxesShares" xlink:label="loc_OCXSharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxesShares_50"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockIssuedDuringPeriodValueAcquisitionsOne" xlink:label="loc_OCXStockIssuedDuringPeriodValueAcquisitionsOne_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodValueAcquisitionsOne_50" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockIssuedDuringPeriodSharesAcquisitionsOne" xlink:label="loc_OCXStockIssuedDuringPeriodSharesAcquisitionsOne_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodSharesAcquisitionsOne_50" xlink:type="arc" order="22"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockIssuedDuringPeriodValueAcquisitionsTwo" xlink:label="loc_OCXStockIssuedDuringPeriodValueAcquisitionsTwo_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodValueAcquisitionsTwo_50" xlink:type="arc" order="23"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockIssuedDuringPeriodSharesAcquisitionsTwo" xlink:label="loc_OCXStockIssuedDuringPeriodSharesAcquisitionsTwo_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodSharesAcquisitionsTwo_50" xlink:type="arc" order="24"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_AdjustmentstoForeignCurrencyTranslation" xlink:label="loc_OCXAdjustmentstoForeignCurrencyTranslation_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXAdjustmentstoForeignCurrencyTranslation_50" xlink:type="arc" order="25"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:title="00000008 - Disclosure - Organization, Description of the Business and Liquidity"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinations" xlink:title="00000010 - Disclosure - Business Combinations"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/GoodwillAndIntangibleAssetsNet" xlink:title="00000011 - Disclosure - Goodwill and Intangible Assets, net"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - Shareholders’ Equity"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensation" xlink:title="00000013 - Disclosure - Stock-Based Compensation"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk" xlink:title="00000014 - Disclosure - Disaggregation of Revenues and Concentration Risk"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:title="00000016 - Disclosure - Right-of-use Assets, Machinery and Equipment, Net and Construction in Progress"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - Commitments and Contingencies"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - Related Party Transactions"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" xlink:title="00000019 - Disclosure - Loan Payable to Silicon Valley Bank"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/QuarterlyFinancialData" xlink:title="00000020 - Disclosure - Quarterly Financial Data (unaudited)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - Subsequent Events"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinationsTables" xlink:title="00000024 - Disclosure - Business Combinations (Tables)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_InsightMergerMember" xlink:label="loc_OCXInsightMergerMember_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXInsightMergerMember_10" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_ChronixBiomedicalIncMember" xlink:label="loc_OCXChronixBiomedicalIncMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXChronixBiomedicalIncMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_ChronixMergerMember" xlink:label="loc_OCXChronixMergerMember_30"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXChronixMergerMember_30" xlink:type="arc" order="31"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_ScheduleOfFairValueOfAggregateMergerConsiderationTableTextBlock" xlink:label="loc_OCXScheduleOfFairValueOfAggregateMergerConsiderationTableTextBlock_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXScheduleOfFairValueOfAggregateMergerConsiderationTableTextBlock_50" xlink:type="arc" order="0"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_50" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_ScheduleOfIdentifiableIntangibleAssetsAndEstimatedUsefulLifeTableTextBlock" xlink:label="loc_OCXScheduleOfIdentifiableIntangibleAssetsAndEstimatedUsefulLifeTableTextBlock_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXScheduleOfIdentifiableIntangibleAssetsAndEstimatedUsefulLifeTableTextBlock_50" xlink:type="arc" order="2"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_50" xlink:type="arc" order="3"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" xlink:label="loc_OCXScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_50" xlink:type="arc" order="4"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaapAssetAcquisitionTableTextBlock_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionTableTextBlock_50" xlink:type="arc" order="5"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="loc_srtScheduleOfCondensedIncomeStatementTableTextBlock_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_srtScheduleOfCondensedIncomeStatementTableTextBlock_50" xlink:type="arc" order="6"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/GoodwillAndIntangibleAssetsNetTables" xlink:title="00000025 - Disclosure - Goodwill and Intangible Assets, net (Tables)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensationTables" xlink:title="00000026 - Disclosure - Stock-Based Compensation (Tables)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_TwoThousandTenPlanActivityMember" xlink:label="loc_OCXTwoThousandTenPlanActivityMember_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandTenPlanActivityMember_10" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_TwoThousandEighteenPalnActivityMember" xlink:label="loc_OCXTwoThousandEighteenPalnActivityMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandEighteenPalnActivityMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="0"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_SchduleOfStockOptionsOutstandingVestedAndExercisableTableTextBlock" xlink:label="loc_OCXSchduleOfStockOptionsOutstandingVestedAndExercisableTableTextBlock_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXSchduleOfStockOptionsOutstandingVestedAndExercisableTableTextBlock_40" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_40" xlink:type="arc" order="2"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" xlink:type="arc" order="3"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:title="00000027 - Disclosure - Disaggregation of Revenues and Concentration Risk (Tables)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - Income Taxes (Tables)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:title="00000029 - Disclosure - Right-of-use Assets, Machinery and Equipment, Net and Construction in Progress (Tables)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesTables" xlink:title="00000030 - Disclosure - Commitments and Contingencies (Tables)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/QuarterlyFinancialDataTables" xlink:title="00000031 - Disclosure - Quarterly Financial Data (unaudited) (Tables)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:title="00000032 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_RazorGenomicsIncMember" xlink:label="loc_OCXRazorGenomicsIncMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXRazorGenomicsIncMember_0" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_PiperSandlerAndCoMember" xlink:label="loc_OCXPiperSandlerAndCoMember_30"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXPiperSandlerAndCoMember_30" xlink:type="arc" order="32"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_SiliconValleyBankMember" xlink:label="loc_OCXSiliconValleyBankMember_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXSiliconValleyBankMember_50" xlink:type="arc" order="52"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_BTIGLLCMember" xlink:label="loc_OCXBTIGLLCMember_70"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXBTIGLLCMember_70" xlink:type="arc" order="72"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_ATMAgreementMember" xlink:label="loc_OCXATMAgreementMember_30"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXATMAgreementMember_30" xlink:type="arc" order="31"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_AtTheMarketSalesAgreementMember" xlink:label="loc_OCXAtTheMarketSalesAgreementMember_70"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXAtTheMarketSalesAgreementMember_70" xlink:type="arc" order="71"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_PaycheckProtectionProgramMember" xlink:label="loc_OCXPaycheckProtectionProgramMember_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_OCXPaycheckProtectionProgramMember_50" xlink:type="arc" order="51"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_110" xlink:type="arc" order="0"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_110" xlink:type="arc" order="1"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_110" xlink:type="arc" order="2"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_110" xlink:type="arc" order="3"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_110" xlink:type="arc" order="4"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi_110"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_110" xlink:type="arc" order="6"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock_110" xlink:type="arc" order="7"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt_110" xlink:type="arc" order="8"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_110" xlink:type="arc" order="9"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_110" xlink:type="arc" order="10"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_GainsOnExtinguishmentOfDebt" xlink:label="loc_OCXGainsOnExtinguishmentOfDebt_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_OCXGainsOnExtinguishmentOfDebt_110" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_110" xlink:type="arc" order="12"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_110" xlink:type="arc" order="13"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_110" xlink:type="arc" order="14"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000033 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="00000034 - Disclosure - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:title="00000035 - Disclosure - Schedule of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share of Common Stock (Details)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockOptionsMember" xlink:label="loc_OCXStockOptionsMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_OCXStockOptionsMember_0" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" xlink:type="arc" order="0"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000036 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_LineageMember" xlink:label="loc_OCXLineageMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_OCXLineageMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_AgeXTherapeuticsIncMember" xlink:label="loc_OCXAgeXTherapeuticsIncMember_30"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_RazorGenomicsIncMember" xlink:label="loc_OCXRazorGenomicsIncMember_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXRazorGenomicsIncMember_50" xlink:type="arc" order="51"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_RazorMember" xlink:label="loc_OCXRazorMember_60"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_OCXRazorMember_60" xlink:type="arc" order="61"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_160"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="4"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_70"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_70" xlink:type="arc" order="71"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_90"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_90" xlink:type="arc" order="91"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_70"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_70" xlink:type="arc" order="72"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_80"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_80" xlink:type="arc" order="82"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="6"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_110" xlink:type="arc" order="111"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="7"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_120"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_120" xlink:type="arc" order="121"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_180" xlink:type="arc" order="0"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:label="loc_OCXCommonStockSharesHeldAsAvailableForSaleSecurities_180"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_OCXCommonStockSharesHeldAsAvailableForSaleSecurities_180" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi_180"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNi_180" xlink:type="arc" order="2"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment_180"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment_180" xlink:type="arc" order="3"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_180" xlink:type="arc" order="4"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_180"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_180" xlink:type="arc" order="5"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_180"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_180" xlink:type="arc" order="6"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_180"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_180" xlink:type="arc" order="7"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_180"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_180" xlink:type="arc" order="8"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_180"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_180" xlink:type="arc" order="9"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableSale" xlink:label="loc_us-gaapAccountsReceivableSale_180"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsReceivableSale_180" xlink:type="arc" order="10"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFairValueOfAggregateMergerConsiderationDetails" xlink:title="00000037 - Disclosure - Schedule of Fair Value of Aggregate Merger Consideration (Details)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_InsightMergerAgreementsMember" xlink:label="loc_OCXInsightMergerAgreementsMember_0"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_ChronixBiomedicalIncMember" xlink:label="loc_OCXChronixBiomedicalIncMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXChronixBiomedicalIncMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:label="loc_us-gaapCashAcquiredInExcessOfPaymentsToAcquireBusiness_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCashAcquiredInExcessOfPaymentsToAcquireBusiness_50" xlink:type="arc" order="0"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_50" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfPerShare" xlink:label="loc_OCXBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfPerShare_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfPerShare_50" xlink:type="arc" order="2"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_50" xlink:type="arc" order="3"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_BusinessCombinationContingentConsiderationArrangementsBasisForAmounts" xlink:label="loc_OCXBusinessCombinationContingentConsiderationArrangementsBasisForAmounts_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXBusinessCombinationContingentConsiderationArrangementsBasisForAmounts_50" xlink:type="arc" order="4"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_FairValueOfConsiderationTransferredOnMergerDate" xlink:label="loc_OCXFairValueOfConsiderationTransferredOnMergerDate_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXFairValueOfConsiderationTransferredOnMergerDate_50" xlink:type="arc" order="5"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_BusinessCombinationAcquireeActivityPreCombinationNet" xlink:label="loc_OCXBusinessCombinationAcquireeActivityPreCombinationNet_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXBusinessCombinationAcquireeActivityPreCombinationNet_50" xlink:type="arc" order="6"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFairValueOfAggregateMergerConsiderationDetailsParenthetical" xlink:title="00000038 - Disclosure - Schedule of Fair Value of Aggregate Merger Consideration (Details) (Parenthetical)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_CashHoldbackMember" xlink:label="loc_OCXCashHoldbackMember_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXCashHoldbackMember_10" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_StockHoldbackMember" xlink:label="loc_OCXStockHoldbackMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXStockHoldbackMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_PaymentsOfCashConsideration" xlink:label="loc_OCXPaymentsOfCashConsideration_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXPaymentsOfCashConsideration_40" xlink:type="arc" order="0"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_EscrowAccountDepositShares" xlink:label="loc_OCXEscrowAccountDepositShares_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXEscrowAccountDepositShares_40" xlink:type="arc" order="1"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfIntangibleAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="00000039 - Disclosure - Schedule of Intangible Assets Acquired and Liabilities Assumed (Details)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfIdentifiableIntangibleAssetsAndEstimatedUsefulLifeDetails" xlink:title="00000040 - Disclosure - Schedule of Identifiable Intangible Assets and Estimated Useful Life (Details)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:type="arc" order="10" xbrldt:closed="true"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentMember_0" xlink:type="arc" order="1"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_10" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_FiniteLivedIntangibleAssetEstimatedFairValue" xlink:label="loc_OCXFiniteLivedIntangibleAssetEstimatedFairValue_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_OCXFiniteLivedIntangibleAssetEstimatedFairValue_40" xlink:type="arc" order="0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_40" xlink:type="arc" order="1"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:title="00000041 - Disclosure - Schedule of Fair Value of Contingent Consideration Liability (Details)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_MilestoneOneMember" xlink:label="loc_OCXMilestoneOneMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXMilestoneOneMember_0" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_MilestoneTwoMember" xlink:label="loc_OCXMilestoneTwoMember_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXMilestoneTwoMember_10" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_MilestoneThreeMember" xlink:label="loc_OCXMilestoneThreeMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXMilestoneThreeMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_RoyaltyOneMember" xlink:label="loc_OCXRoyaltyOneMember_30"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXRoyaltyOneMember_30" xlink:type="arc" order="31"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_RoyaltyTwoMember" xlink:label="loc_OCXRoyaltyTwoMember_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXRoyaltyTwoMember_40" xlink:type="arc" order="41"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_ContingentConsiderationLiabilityContractualValue" xlink:label="loc_OCXContingentConsiderationLiabilityContractualValue_70"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXContingentConsiderationLiabilityContractualValue_70" xlink:type="arc" order="0"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_70"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_70" xlink:type="arc" order="1"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:title="00000042 - Disclosure - Schedule of Contingent Consideration, Measured at Fair Value (Details)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_InsightMergerMember" xlink:label="loc_OCXInsightMergerMember_0"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_ChronixMergerMember" xlink:label="loc_OCXChronixMergerMember_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXChronixMergerMember_50" xlink:type="arc" order="52"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_90" xlink:type="arc" order="0"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_90"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_90" xlink:type="arc" order="1"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfAcquisitionIntangibleAssetsDetails" xlink:title="00000043 - Disclosure - Schedule of Acquisition Intangible Assets (Details)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_RazorGenomicsIncMember" xlink:label="loc_OCXRazorGenomicsIncMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXRazorGenomicsIncMember_0" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaapEquityMethodInvestments_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestments_20" xlink:type="arc" order="0"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_CashPaidAsAdditionalPurchasePaymentForRazorAsset" xlink:label="loc_OCXCashPaidAsAdditionalPurchasePaymentForRazorAsset_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXCashPaidAsAdditionalPurchasePaymentForRazorAsset_20" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue_20" xlink:type="arc" order="2"/>

<link:loc xlink:type="locator" xlink:href="ocx-20211231.xsd#OCX_CashBalanceReceivedFromRazorForClinicalTrialExpenses" xlink:label="loc_OCXCashBalanceReceivedFromRazorForClinicalTrialExpenses_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXCashBalanceReceivedFromRazorForClinicalTrialExpenses_20" xlink:type="arc" order="3"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilities_20" xlink:type="arc" order="4"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapOtherFiniteLivedIntangibleAssetsGross_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherFiniteLivedIntangibleAssetsGross_20" xlink:type="arc" order="5"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_20" xlink:type="arc" order="6"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfAcquisitionIntangibleAssetsDetailsParenthetical" xlink:title="00000044 - Disclosure - Summary of Acquisition Intangible Assets (Details) (Parenthetical)">